文献速递前列腺癌

局限性前列腺癌根治术后5年PSA监测的种族差异

Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-03

基于SEER-Medicare数据库2007-2011年诊断并随访至2016年的21,372例局限性前列腺癌患者,采用多因素对数二项回归分析种族对根治术后5年内每年至少一次PSA监测未实施概率的影响。黑人男性在术后第1至第4年未接受年度PSA监测的风险均显著高于白人男性,提示需改进黑人幸存者的随访照护计划。

要点

  • 黑人男性根治术后第1年未做年度PSA监测的风险比白人高90%。
  • 第2至第4年未监测风险仍分别增加71%、44%、34%,差异持续存在。
  • 研究提示应针对黑人男性优化幸存者照护计划以提高PSA监测依从性。

核心结论

  • 黑人男性在局限性前列腺癌根治术后前4年更可能未接受指南一致的PSA监测。
  • 研究提示需改进黑人男性的幸存者照护计划以提高PSA监测使用率。

研究设计与样本

  • 基于SEER-Medicare链接数据库构建的人群基础回顾性队列。
  • 纳入2007至2011年诊断的局限性前列腺癌男性,随访至2016年,共21,372例。
  • 采用多因素对数二项回归模型分析种族对术后5年内每年至少一次PSA监测未实施概率的影响。

主要发现

  • 黑人男性术后第1、2、3、4、5年未接受至少一次年度PSA监测的风险分别增加90%、71%、44%、34%、23%。
  • 校正后相对风险(ARR)在术后第1年为1.68(95%CI 1.37-2.07),第2年为1.52(95%CI 1.32-1.75),第3年为1.32(95%CI 1.17-1.48),第4年为1.16(95%CI 1.05-1.29)。

临床怎么用

  • 泌尿外科医生应关注黑人男性前列腺癌根治术后PSA监测依从性,尤其在术后前4年。
  • 可针对黑人幸存者制定更完善的随访照护计划以缩小监测差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific antigen (PSA) surveillance testing is a cornerstone of prostate cancer survivorship because patients with biochemical recurrence often have no symptoms. However, the investigation of guideline-concordant PSA surveillance across racial groups is limited. We examined racial differences in PSA surveillance testing 5-years post-definitive treatment for localized prostate cancer. METHODS: We created a population-based retrospective cohort from the Surveillance, Epidemiology, and End Results-Medicare linked database for men diagnosed with prostate cancer between the years 2007 to 2011 with Medicare claims through 2016 (N = 21,372). Multivariable log-binomial regression models were used to examine the effect of race on the likelihood of not receiving at least one PSA surveillance test annually 5-years post-definitive treatment. RESULTS: Black men had 90%, 71%, 44%, 34%, and 23% increased risk of not receiving at least one PSA surveillance test annually in the first, second, third, fourth, and fifth years of post-definitive treatment follow-up, respectively. The adjusted relative risk [ARR] for Black men compared to White men were 1.68 (95% Confidence Interval [CI], 1.37-2.07), 1.52 (95% CI, 1.32-1.75), 1.32 (95% CI, 1.17-1.48), and 1.16 (95% CI, 1.05-1.29) in the first, second, third, and fourth year of post-definitive treatment, respectively. CONCLUSION: Black men were more likely not to receive guideline-concordant PSA surveillance testing following definitive treatment for localized prostate cancer during the first 4 years post-treatment. This study suggest room for improvement in defining survivorship care plans for Black men to increase use of PSA surveillance testing.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Asiri IM, Chen RC, Young HN, et al. Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33941865. doi:10.1038/s41391-021-00365-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。